Speaker Biography

Mouad Edderkaoui

Cedars-Sinai Medical Center & University of California Los Angeles, USA

Title: Targeting metastasis and drug resistance for treating pancreatic cancer

Mouad Edderkaoui

Dr. Mouad Edderkaoui PhD has research goal to understand the mechanism of pancreatic cancer initiation and progression and to develop a treatment strategy for the disease. Edderkaoui focuses on the role of cells present in the tumor microenvironment and how histone deacetylases (HDACs) regulate the interaction between these cells. He currently  belongs to Cedars-Sinai Medical Center & University of California Los Angeles, USA.

He was awarded with career development award, national institute of health in 2011, Hirshberg foundation award in 2012 and at-present he is the Associate editor: Frontiers in science.


Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with no effective treatment. PDAC cells are highly proliferative and metastatic. We have developed a new drug called Metavert that targets, at the same time, the glycogen synthase kinase 3 beta (GSK-3β) and histone deacetylase (HDAC- class 1/2), important mediators of cancer progression.

We have designed and synthesized a novel drug that shows a significant anti-cancer effect in vitro in PDAC cells and patient-derived circulating tumor cells (CTCs) and in vivo in the most aggressive mouse model of experimental PDAC using the KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdxcre (KPC) mice.

Metavert significantly (at nano-molar concentrations) decreased cancer cell survival and increased apoptosis in several PDAC cells lines and CTCs. The same doses of Metavert did not affect survival of normal hepatocytes and pancreatic ductal cells. Metavert decreased expression of markers of epithelial to mesenchymal transition (EMT) and cancer stemness, the two driving forces of metastasis and drug resistance. Metavert prevented invasion of the cancer cell lines. Furthermore, Metavert sensitized PDAC cells and CTCs to chemotherapy drugs gemcitabine and paclitaxel. Treatment with Metavert significantly increased KPC mice survival by ~50% and sensitized the tumors to gemcitabine. Distal metastasis was decreased from 29% in control KPC mice to 0% in Metavert treated KPC mice. Fibrosis, M2 macrophages, and pro-cytokine levels in the blood were decreased by Metavert treatment without affecting the function of healthy organs.

Avenzoar Pharmaceuticals has licensed Metavert and it has obtained the orphan drug status for it. The pre-clinical PK, PD, toxicity studies are ongoing and the drug is expected to be approved for clinical testing within one year.